KR20100018174A - Skin external composition containing taraxacum platycarpum h. dahlsi, cimicifuga heracleifolia, dioscorea opposita or angelica tenuissima nakai - Google Patents

Skin external composition containing taraxacum platycarpum h. dahlsi, cimicifuga heracleifolia, dioscorea opposita or angelica tenuissima nakai Download PDF

Info

Publication number
KR20100018174A
KR20100018174A KR1020080076826A KR20080076826A KR20100018174A KR 20100018174 A KR20100018174 A KR 20100018174A KR 1020080076826 A KR1020080076826 A KR 1020080076826A KR 20080076826 A KR20080076826 A KR 20080076826A KR 20100018174 A KR20100018174 A KR 20100018174A
Authority
KR
South Korea
Prior art keywords
extract
pogongyoung
skin
horse riding
herbal
Prior art date
Application number
KR1020080076826A
Other languages
Korean (ko)
Other versions
KR101047644B1 (en
Inventor
김수정
노호식
김은주
문은정
조가영
권이경
김연준
김덕희
김한곤
Original Assignee
(주)아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)아모레퍼시픽 filed Critical (주)아모레퍼시픽
Priority to KR1020080076826A priority Critical patent/KR101047644B1/en
Publication of KR20100018174A publication Critical patent/KR20100018174A/en
Application granted granted Critical
Publication of KR101047644B1 publication Critical patent/KR101047644B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288Taraxacum (dandelion)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/71Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9794Liliopsida [monocotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

PURPOSE: A skin external composition containing medicinal herb extract is provided to promote regeneration of wound tissue and suppress skin injury and aging. CONSTITUTION: A skin external composition for anti-inflammation contains medicinal herbs including Taraxacum platycarpum H. Dahlsi, Cimicifuga heracleifolia, Dioscorea opposite, or Angelica tenuissima Nakai extract as an active ingredient. The skin external composition for wound healing and anti-aging contains the medicinal herbs. The medicinal herb extract is obtained using water or organic solvent. The organic solvent is ethanol, methanol, butanol, ether, ethylacetate, or chloroform.

Description

포공영, 승마, 산약 또는 고본 추출물을 함유하는 피부 외용제 조성물{Skin external composition containing Taraxacum platycarpum H. Dahlsi, Cimicifuga heracleifolia, Dioscorea opposita or Angelica tenuissima Nakai}Skin external composition containing Tarexacum platycarpum H. Dahlsi, Cimicifuga heracleifolia, Dioscorea opposita or Angelica tenuissima Nakai}

본 발명은 포공영, 승마, 산약 및 고본 추출물 중 1종 이상의 한약재 추출물을 유효성분으로 함유함으로써 염증 관련 인자들을 억제시키는 항염증 효능을 가지고, 상처 조직의 재상피화를 촉진시켜 염증기에서 증식기로의 진행을 빠르게 도와주는 상처치료 효능을 가지며, 해독 작용에 관여하는 효소들의 유전자 발현을 증가시켜 UV 등 외부 자극에 의한 피부 손상을 억제하여 피부 노화를 억제하는 항노화 효능을 가지는 피부 외용제 조성물에 관한 것이다.The present invention has an anti-inflammatory effect of inhibiting inflammation-related factors by containing one or more herbal extracts of pogongyoung, horse riding, powder and herbal extracts as an active ingredient, and promotes re-epithelialization of wound tissues to promote progression from inflammatory phase to proliferation. The present invention relates to an external composition for skin having an anti-aging effect of rapidly healing wounds and increasing gene expression of enzymes involved in detoxification, thereby inhibiting skin damage caused by external stimuli such as UV and inhibiting skin aging.

피부는 외부로부터 신체를 보호하는 방어막으로서 역할을 한다. 피부에 상처가 생기면 생체의 자연 치유 작용에 의해 상처자리를 혈액이 채우게 되고 혈소판의 과립감소와 하게만 인자(hageman factor)의 활성화가 시작되어 상처 치유 과정이 진행된다. 혈액의 응고는 임시 방어 작용으로서, 노출된 상처 조직들을 보호하고 치유 과정 동안 세포들이 이동할 수 있는 기반을 제공한다(Lee SH AS, Jung SG. Skin Barrier. Seoul: Ryo Moon Gak, 2004).The skin acts as a shield to protect the body from the outside. When a wound occurs on the skin, the blood fills the wound site by the natural healing action of the living body, the granule reduction of platelets and activation of the hageman factor are initiated, and the wound healing process proceeds. Blood coagulation is a temporary protective action that protects exposed wound tissues and provides a basis for cells to migrate during the healing process (Lee SH AS, Jung SG. Skin Barrier. Seoul: Ryo Moon Gak, 2004).

상처치유 과정은 크게 염증기, 재상피화기, 증식기 및 성숙기의 4단계로 구분된다. 염증기 동안에는 상처 자리에 면역 세포들이 출현하는데, 이 세포들은 혈관으로부터 상처 부위로 이동한 것이다. 이어 과립조직 형성을 유도하는 성장인자와 신호전달 물질들이 분비된다. 중대한 감염이 없는 상태에서는 염증기가 일반적으로 짧게 진행된다(Care KRGf.Advances in wound Care. Seoul: Korea Medical Book Publisher, 2002). 염증기는 상처치료 과정에 꼭 필요한 단계이다.The wound healing process is divided into four stages: inflammatory, re-epithelial, proliferative and mature stages. During the inflammatory phase, immune cells appear in the wound site, which have migrated from blood vessels to the wound site. Subsequently, growth factors and signaling substances that induce granulation formation are secreted. In the absence of serious infections, the inflammatory phase usually progresses briefly (Care KRGf. Advances in wound Care. Seoul: Korea Medical Book Publisher, 2002). Inflammation is an essential step in the healing process.

증식기는 재상피화기와 비슷하게 일어나게 되는데 상처 부위에서 과립 조직들이 형성되는 특성을 나타낸다(Kubo KKY. Spongy matrix of hyaluronic acid and collagen as a cultured dermal substitute: evaluation in an animal test. J Artif Organs 2003;6(1):64-70). 과립조직들은 섬유아세포(fibroblasts) 및 염증성 세포(inflammatory cells)와 함께 미성숙 콜라겐(immaturity collagen), 피브로넥틴(fibronectin) 및 히알루론산(hyaluronic acid) 등의 세포외기질 구성요소들의 조합으로 이루어져 있고 이 과립조직들이 상처부분을 빠르게 채우고 조직적인 구조를 갖추는 것이 상처치료에 중요하다. 벗겨진 상처 표면이 각질형성세포(keratinocytes) 층에 의해 덮이면서 새로운 표피가 생성되고 상피층이 재건되게 된다. 세포들은 상처 가장자리 또는 남겨진 피부의 진피 잔여물에서 상처를 통하여 떠올라 딱지 아래와 살아있는 결합 조직 위를 통하여 이주를 시작한다.The proliferative phase occurs similarly to re-epithelialization, which is characterized by the formation of granular tissues at the wound site (Kubo KKY.Spongy matrix of hyaluronic acid and collagen as a cultured dermal substitute: evaluation in an animal test. J Artif Organs 2003; 6 (1) ): 64-70). Granulation tissue consists of a combination of extracellular matrix components such as immaturity collagen, fibronectin and hyaluronic acid, together with fibroblasts and inflammatory cells. It is important to treat the wound quickly and to have a structured structure. The exfoliated wound surface is covered by a layer of keratinocytes, creating a new epidermis and reconstructing the epidermal layer. Cells rise through the wound at the edge of the wound or the dermal residue of the skin left and begin migration through the crust and above the living connective tissue.

상처의 재상피화가 완료되면 결합조직의 증가와 재편성을 통해 상처 면적이 감소되는 일련의 과정들이 진행되게 된다. 그 후, 성숙기 동안에는 회복기 조직의 엉긴 세포들과 모세혈관들이 조금씩 사라지게 되는데 이런 조직들이 과형성되거나 정상적으로 분해되지 않을 경우 흉터가 생기게 된다. 이것이 일반적인 상처치료 과정이다. 상처 치유과정에서는 상처를 빠르게 치료하는 것뿐만 아니라 부작용이나 흉터 없이 치료하는 것이 중요하기 때문에 염증의 억제와 성장 인자들의 발현 조절을 통해 조직세포들이 균형 있게 채워져 나가는 것이 더욱 중요하며, 이러한 효능을 가지는 물질을 찾고자 하는 노력이 계속 진행되고 있다. When the re-epithelialization of the wound is completed, a series of processes are performed in which the wound area is reduced through the increase and reorganization of connective tissue. Then, during the maturation phase, the convoluted cells and capillaries of the convalescent tissue gradually disappear, causing scarring if these tissues are hyperplastic or do not degrade normally. This is a common wound healing process. In the wound healing process, it is important not only to treat the wound quickly but also to treat it without side effects or scars, so that the tissue cells are balanced and balanced by suppressing inflammation and regulating the expression of growth factors. Efforts to find this continue.

염증의 감소는 염증성 세포 유형, 예컨대 단핵 세포 또는 성상세포, 호중구, 비만 세포, 호염기성 세포의 밀도 감소에 의해 측정될 수 있다. 또한 호중구 활성의 측정을 통해서도 염증 감소를 측정할 수 있으며(Jones et al., 1994), 비만 세포 탈과립화의 빈도 또는 히스타민 수준의 측정 또는 반응성 산소종의 수준과 같은 인자들도 염증 감소의 척도로서 사용될 수 있다. 염증의 수준은 또한 PCR에 의해 특정 유전자, 예컨대 인터페론-α, -β 및 -γ, 종양 괴사 인자-α, 인터류킨 1β, -2, -4, -5, -6, -8, -12, -18, -23, -27, CD4, CD28, CD80, CD86, MHCII, 및 iNOS와 같은 유전자의 전사 수준을 체크함으로써 간접적으로 측정될 수 있다. 조직 및/또는 환자의 유체, 이를테면 혈장 내 전염증성 사이토카인(proinflammatory cytokines) 수준의 측정은 염증 감소의 척도일 수 있다.Reduction in inflammation can be measured by decreasing the density of inflammatory cell types such as mononuclear cells or astrocytes, neutrophils, mast cells, basophil cells. Inflammation reduction can also be measured by measuring neutrophil activity (Jones et al., 1994), and factors such as the frequency of mast cell degranulation or the measurement of histamine levels or the level of reactive oxygen species are also measured as a measure of inflammation reduction. Can be used. The level of inflammation can also be determined by PCR for certain genes such as interferon-α, -β and -γ, tumor necrosis factor-α, interleukin 1β, -2, -4, -5, -6, -8, -12,- Can be measured indirectly by checking the transcriptional levels of genes such as 18, -23, -27, CD4, CD28, CD80, CD86, MHCII, and iNOS. Determination of proinflammatory cytokines levels in tissues and / or patients' fluids, such as plasma, may be a measure of inflammation reduction.

최근 피부의 내재적인 염증 매개인자와 노화 사이의 상관관계에 대하여 보고되었다. 특히 염증 매개인자인 종양 괴사 인자-α와 인터류킨 1β는 콜라게나아제-1(MMP-1) 및 콜라게나아제-3(MMP-3)을 포함한 여러 매트릭스 메탈로프로테아 제(MMPs: matrix metalloproteinases)의 생성을 증가시키고, 콜라겐과 피브로넥틴(fibronectin) 합성을 저하시키는 것으로 보고되었다(Wan et al., Transmodulation of epidermal growth factor receptor mediates IL-1 beta-induced MMP-1 expression in cultured human keratinocytes. Int J Mol Med. 2001 Mar;7(3):329-34; Tanaka et al., Prevention of the ultraviolet B-mediated skin photoaging by a nuclear factor kappaB inhibitor, parthenolide. J Pharmacol Exp Ther. 2005 Nov;315(2):624-30. Epub 2005 Jul 18; 및 Kong et al., Cyclophilin C-associated protein is a mediator for fibronectin fragment-induced matrix metalloproteinase-13 expression. J Biol Chem. 2004 Dec 31;279(53):55334-40. Epub 2004 Oct 26).Recently, the correlation between the intrinsic inflammatory mediators of skin and aging has been reported. In particular, inflammatory mediators, tumor necrosis factor-α and interleukin 1β, are matrix metalloproteinases (MMPs) including collagenase-1 (MMP-1) and collagenase-3 (MMP-3). It has been reported to increase the production of and to decrease collagen and fibronectin synthesis (Wan et al., Transmodulation of epidermal growth factor receptor mediates IL-1 beta-induced MMP-1 expression in cultured human keratinocytes.Int J Mol 2001 Mar; 7 (3): 329-34; Tanaka et al., Prevention of the ultraviolet B-mediated skin photoaging by a nuclear factor kappaB inhibitor, parthenolide.J Pharmacol Exp Ther. 2005 Nov; 315 (2): Epub 2005 Jul 18; and Kong et al., Cyclophilin C-associated protein is a mediator for fibronectin fragment-induced matrix metalloproteinase-13 expression.J Biol Chem. 2004 Dec 31; 279 (53): 55334-40 Epub 2004 Oct 26).

종양 괴사 인자-α 및 인터류킨 1β는 염증 신호전달인자의 합성을 조절하는 전사인자인 NF-κB의 활성 조절을 통해 세포 내의 MMPs 생성을 유도하여 세포간기질의 분해를 촉진한다고 보고되었다. 따라서 종양 괴사 인자-α, 인터류킨 1β 생성과 NF-κB 활성에 의한 MMPs 생성과 매트릭스 단백질의 생성 저해는 노화된 피부의 콜라겐 부족 현상과 연관되어 있음이 제안될 수 있다. 염증성 사이토카인의 합성 저하와 전사인자 NF-κB의 활성 저하를 통해 MMP-1의 생성을 억제시키는 약물은 노화 방지제로서 활용이 가능하다. Tumor necrosis factor-α and interleukin 1β have been reported to promote the degradation of intercellular matrix by inducing the production of MMPs in cells through the regulation of NF-κB, a transcription factor that regulates the synthesis of inflammatory signaling factors. Therefore, it may be suggested that inhibition of MMPs production and matrix protein production by tumor necrosis factor-α, interleukin 1β production and NF-κB activity is associated with collagen deficiency in aged skin. Drugs that inhibit the production of MMP-1 through reduced synthesis of inflammatory cytokines and reduced transcription factor NF-κB activity can be used as anti-aging agents.

포공영(蒲公英, Taraxacum platycarpum H. Dahlsi)은 민들레, 황화지정, 지정 또는 포공초 등으로 불리며, 열독을 내리고 종기를 삭히는 기능, 항염증, 간보호 효능 및 카드뮴 해독 작용 등이 보고되었다. 또한 황달, 종창, 홍역 치유 효과 및 머리를 다시 검게 하는 효능 등이 전해지고 있다. 한국공개특허공보 특2002-44266호에는 포공영을 포함하는 복합생약 추출물을 포함하고 피부 노화 및 주름살을 방지하고 미백효과가 우수한 피부 보호용 화장품 조성물이 개시되어 있다.Pogong-young (蒲公英, Taraxacum platycarpum H. Dahlsi) has been reported, such as dandelion, sulfide specified, or specified as referred pogong seconds or the like, makes a Reading function sakhineun the boil, anti-inflammatory, between protective efficacy and cadmium detoxification. In addition, jaundice, swelling, measles healing effect and the effect of blackening the hair is said to be. Korean Laid-Open Patent Publication No. 2002-44266 discloses a cosmetic composition comprising a complex herbal extract including pogongyoung, preventing skin aging and wrinkles, and having excellent whitening effect.

승마(升麻, Cimicifuga heracleifolia)는 위로 상승하는 작용이 있어 '승(升, 오르다)마'라 한다. 본초강목에는 '승마는 성한하다. 위를 맑게 하며 독을 풀고 올라가서 치아의 동통도 가시게 한다'고 기술되어 있다. 그 성질이 가볍고 위로 뜨는 특징이 있어서 양기를 위로 올리는 효능과 우리 몸의 겉부분인 표를 풀어 헤쳐주는 효능 및 열을 내리고 해독하는 효능이 있다. 주로 풍열로 인한 두통과 치통등에 사용되며 입안이 헌데, 인후가 아플 때, 마진 초기, 항문이나 직장의 점막 또는 전층이 밖으로 나오는 탈항 등에 이용한다. 또한 해독의 작용이 강하여 석고나 대청엽과 같이 사용하면 위열로 인한 치통이나 발광 등의 증상을 억제한다.Horseback riding (升麻, Cimicifuga heracleifolia) has a function to rise upwards, it is called 'seung (rise) horse.' In the main river, horseback riding is hard. It clears the stomach, loosens the poison and goes up to make the pain of teeth go away. ' Its light and floating nature has the effect of raising the amount of yang up, the effect of releasing the table outside the body of the body and the effect of lowering and detoxifying heat. It is mainly used for headaches and toothaches caused by wind fever, and when the mouth is sore, when the throat hurts, it is used for the initial margin, marginal discharge of the mucous membranes or anterior layers of the anus or rectum. In addition, the strong detoxification action, such as gypsum and large blue leaves to suppress symptoms such as toothache or luminescence caused by stomach fever.

산약(山藥, Dioscorea opposita)은 어지러움과 두통, 진정, 체력보강 및 담 제거 등 한방에서 알려진 효능만도 10여 가지에 달 할 정도로 예로부터 약용으로 널리 이용되어 왔다. 자양강장에 특별한 효험이 있고 소화 불량이나 위장장애, 당뇨병, 기침 및 폐질환 등에도 효과가 두드러진다. 특히 신장 기능을 튼튼하게 하는 작용이 강해 원기가 쇠약한 사람이 오래 복용하면 좋다고 한다. 근골을 튼튼하게 하며, 정신을 안정시키고 의지를 강하게 한다고 동의보감에 나와 있다.Sanos (山藥, Dioscorea opposita) has been widely used in medicine for a long time, such as dizziness, headache, sedation, stamina reinforcement, and phlegm removal, which has more than 10 known effects. It has a special effect on nourishing tonic and is effective in indigestion, gastrointestinal disorders, diabetes, cough and lung diseases. In particular, the kidney function is strong, strong people with weakened energy is good to take longer. They agree that they strengthen the muscles, stabilize the mind and strengthen the will.

고본(藁本, Angelica tenuissima Nakai)은 풍으로 인한 두통을 낫게 하며 안개와 이슬독을 받지 않게 한다. 살을 살아나게 하고 얼굴빛을 좋게 하며 주근깨, 비사증 및 여드름을 없애며 목욕하는 약과 얼굴에 바르는 기름을 만들 수 있다고 동의보감에 기록되어 있다. 또한 한국공개특허공보 제2006-93164호에는 녹두, 백지, 백급, 천화분, 고분 및 조각자의 한약재 추출물을 유효성분으로 포함하여 세포증식 및 콜라겐 합성 촉진에 의한 주름완화 효과가 우수한 주름 완화 화장료 조성물이 개시되어 있다.Ancient book (Angel 本, Angelica tenuissima Nakai) relieves headaches caused by wind and avoids fog and dew poison. It is written in the agreement that it can revive flesh, improve face color, remove freckles, visa and acne, and make bath medicine and oil on face. In addition, Korean Laid-Open Patent Publication No. 2006-93164 discloses an anti-wrinkle cosmetic composition having excellent anti-wrinkle effect by promoting cell proliferation and collagen synthesis by including extracts of medicinal herbs of mung bean, white paper, white powder, cheonhwa powder, tomb and flake as active ingredients. It is.

이에 본 발명자들은 세포 배양 상태에서의 상처치유 측정법(in vitro wound healing assay)을 수행하여 포공영, 승마, 산약 또는 고본 추출물이 염증관련 인자들을 억제시킴으로써 항염증 효능을 보이고, 피부각질형성세포의 분열과 이동을 촉진시킴으로써 염증기에서 증식기로의 진행을 빠르게 도와주어 상처치료 효능을 보이며, 또한 항염증 효과와 함께 해독 작용에 관여하는 효소들의 유전자 발현을 증가시킴으로써 자외선 등 외부 자극에 의한 피부 손상을 억제하여 피부 노화를 억제하는 효능을 가짐을 발견하고 본 발명을 완성하게 되었다.Thus, the present inventors have measured wound healing in a cell culture state ( in By performing in vitro wound healing assay, pogongyoung, horseback riding, powder or herbal extract shows anti-inflammatory effect by inhibiting inflammation-related factors, and accelerates the progression from inflammatory phase to proliferation by promoting division and migration of keratinocytes. The present invention has been shown to have an effect of inhibiting skin aging by inhibiting skin damage caused by external stimuli such as ultraviolet rays by increasing gene expression of enzymes involved in detoxification with anti-inflammatory effects, and completing the present invention. Was done.

따라서, 본 발명의 목적은 염증관련 인자들을 억제시킴으로써 항염증 효능을 가지고, 피부각질형성세포의 분열과 이동을 촉진시킴으로써 염증기에서 증식기로의 진행을 빠르게 도와주어 상처치료 효능을 가지며, 자외선 등 외부 자극에 의한 피부 손상을 억제하여 피부 노화를 억제하는 효능을 가지는 피부 외용제 조성물을 제공하는 것이다.Accordingly, an object of the present invention has anti-inflammatory effects by inhibiting inflammation-related factors, and by promoting the division and migration of the keratinocytes of the skin to facilitate the progression from the inflammatory phase to the proliferative phase has a wound healing effect, external stimulation such as ultraviolet rays It is to provide a skin external preparation composition having the effect of inhibiting skin damage by inhibiting skin aging.

상기 목적을 달성하기 위하여, 본 발명에서는 포공영, 승마, 산약 및 고본 추출물로 이루어진 군에서 선택된 1종 이상의 한약재 추출물을 유효성분으로 함유하는 항염증용 조성물을 제공한다.In order to achieve the above object, the present invention provides an anti-inflammatory composition containing as an active ingredient one or more herbal extracts selected from the group consisting of pogongyoung, horse riding, powdered and herbal extracts.

또 본 발명에서는 포공영, 승마, 산약 및 고본 추출물로 이루어진 군에서 선 택된 1종 이상의 한약재 추출물을 유효성분으로 함유하는 상처 치유용 조성물을 제공한다.In another aspect, the present invention provides a wound healing composition containing as an active ingredient one or more herbal extracts selected from the group consisting of pogongyoung, horse riding, mountain powder and gobon extract.

또한 본 발명에서는 포공영, 승마, 산약 및 고본 추출물로 이루어진 군에서 선택된 1종 이상의 한약재 추출물을 유효성분으로 함유하는 항노화용 조성물을 제공한다.In another aspect, the present invention provides a composition for anti-aging containing one or more herbal extracts selected from the group consisting of pogongyoung, horse riding, powdered herbs and gobon extract as an active ingredient.

본 발명에 의한 포공영, 승마, 산약 및 고본 추출물로 이루어진 군에서 선택된 1종 이상의 한약재 추출물을 함유하는 조성물은 긁힘 상처를 치유하였고, LPS 유도된 세포주 모델에서 염증관련 인자인 iNOS, IL-1β 및 TNF-α의 mRNA 양을 유의성 있게 감소시켰으며, 각질형성세포 성장인자 수용체 유전자의 발현을 증가시킴으로써 항염증 또는 상처 치유 효과를 나타내었다. 또한 본 발명에 의한 조성물은 UV에 의한 NF-κB 활성증가 및 MMP-1 생성 증가를 억제하였고, 노화에 따른 MMP-1의 생성 증가 역시 억제하며 해독 기능을 하는 유전자의 발현을 증가시킴으로써 항노화 효과를 나타내었다. 따라서, 본 발명에 의한 포공영, 승마, 산약 및 고본 추출물은 화장료 조성물 또는 약학 조성물에 유효성분으로 함유됨으로써 우수한 항염증, 상처치유 및 항노화 효과를 제공할 수 있다.The composition containing one or more herbal extracts selected from the group consisting of pogongyoung, horse riding, powder and herbal extracts according to the present invention healed scratch wounds, iNOS, IL-1β and TNF which are inflammation-related factors in LPS-induced cell line model mRNA levels of -α were significantly reduced and anti-inflammatory or wound healing effects were shown by increasing expression of keratinocyte growth factor receptor genes. In addition, the composition according to the present invention inhibits the increase of NF-κB activity and the increase of MMP-1 production by UV, and also inhibits the increase of MMP-1 production with aging and anti-aging effect by increasing the expression of detoxifying genes Indicated. Therefore, pogongyoung, horse riding, powder and extract extract according to the present invention can provide excellent anti-inflammatory, wound healing and anti-aging effect by containing as an active ingredient in the cosmetic composition or pharmaceutical composition.

본 발명에서는 포공영, 승마, 산약 및 고본 추출물로 이루어진 군에서 선택 된 1종 이상의 한약재 추출물을 조성물 총 중량에 대하여 0.0001∼15 중량%로 함유하는 항염증용 조성물을 제공한다.The present invention provides an anti-inflammatory composition containing 0.0001 to 15% by weight of one or more herbal extracts selected from the group consisting of pogongyoung, horse riding, mountain powder and gobon extract based on the total weight of the composition.

또 본 발명에서는 포공영, 승마, 산약 및 고본 추출물로 이루어진 군에서 선택된 1종 이상의 한약재 추출물을 조성물 총 중량에 대하여 0.0001∼15 중량%로 함유하는 상처치료용 조성물을 제공한다.In another aspect, the present invention provides a composition for wound healing containing 0.0001 to 15% by weight relative to the total weight of one or more herbal extracts selected from the group consisting of pogongyoung, horse riding, powdered and kobon extract.

또한 본 발명에서는 포공영, 승마, 산약 및 고본 추출물로 이루어진 군에서 선택된 1종 이상의 한약재 추출물을 조성물 총 중량에 대하여 0.0001∼15 중량%로 함유하는 항노화용 조성물을 제공한다.In another aspect, the present invention provides an anti-aging composition containing 0.0001 to 15% by weight relative to the total weight of the composition of one or more herbal extracts selected from the group consisting of pogongyoung, horse riding, powder and gobon extract.

이하, 본 발명을 구체적으로 보다 상세히 설명한다.Hereinafter, the present invention will be described in detail.

본 발명에서 사용하는 포공영, 승마, 산약 및 고본 추출물은 각 한약재를 물 또는 유기용매로 추출물을 수득할 수 있다. 본 발명에서 사용하는 유기용매는 에탄올, 메탄올, 부탄올, 에테르, 에틸아세테이트 및 클로로포름으로 이루어진 군에서 선택된 하나 이상일 수 있으며, 또는 이들 유기용매와 물과의 혼합용매를 사용할 수도 있다. 바람직하게는 80% 에탄올을 사용할 수 있다.The pogongyoung, horse riding, powder and herbal extracts used in the present invention can be obtained by extracting each herbal medicine with water or an organic solvent. The organic solvent used in the present invention may be one or more selected from the group consisting of ethanol, methanol, butanol, ether, ethyl acetate and chloroform, or a mixed solvent of these organic solvents and water may be used. Preferably 80% ethanol can be used.

본 발명에 의한 피부 외용제 조성물은 상기의 방법으로 추출된 포공영, 승마, 산약 및 고본 추출물로 이루어진 군에서 선택된 1종 이상의 한약재 추출물을 유효성분으로 하여 조성물 총 중량에 대하여 0.0001∼15 중량%의 양으로 함유한다. 상기 추출물의 함량이 0.0001 중량% 미만이면 상기 추출물에 의한 항염, 상처치유, 항노화 효과 등을 얻을 수 없고, 15 중량%를 초과하면 함량 증가에 비해 효과의 증 가가 크지 않기 때문에 비효율적이다. 본 발명에 의한 조성물은 상기 포공영, 승마, 산약 및 고본 추출물을 단독 또는 2종 이상 혼합하여 사용할 수 있으나, 상기 추출물을 단독으로 사용하였을 때보다 2종 이상 혼합하여 사용하였을 때 그 효과가 더 우수하였으며, 바람직하게는 상기 포공영, 승마, 산약 및 고본 추출물을 1:1:1:1의 중량비로 혼합하여 사용하지만, 특별하게 한정하지 않고 제형 내에서 적절한 비율로 혼합하여 사용할 수 있다.The external preparation composition for skin according to the present invention comprises at least one medicinal herb extract selected from the group consisting of pogongyoung, horseback riding, medicinal herb and medicinal extract extracted by the above method as an active ingredient in an amount of 0.0001 to 15% by weight based on the total weight of the composition. It contains. When the content of the extract is less than 0.0001% by weight, anti-inflammatory, wound healing, anti-aging effects, etc. may not be obtained by the extract. When the content of the extract is more than 15% by weight, the increase in effect is not large compared to the increase in content. The composition according to the present invention may be used alone or in combination of two or more of the pogongyoung, horse riding, acid and extract extract, the effect was more excellent when used in combination of two or more than the extract alone. Preferably, the pogongyoung, horse riding, powder and extract extract is used in a weight ratio of 1: 1: 1: 1, but can be used by mixing in an appropriate ratio in the formulation without particular limitation.

본 명세서에서 사용된 "피부 손상" 또는 "상처"라는 용어는 서로 교환하여 사용이 가능하며, 예를 들면, 긁힘, 칼로 베임, 찢어진 상처, 눌린 상처, 압박 상처, 스트레치 손상, 물린 상처, 찰과상, 총탄 상처, 폭발 손상, 바디 피어싱, 찔린 상처, 화상, 바람에 의한 상처, 태양 화상, 화학약품 화상, 수술 상처, 수술적 간섭, 의료용 간섭, 세포, 조직 또는 기관 이식 후 숙주 거부반응, 약제 효과, 약제학적 부작용, 욕창, 방사선 손상, 화장품으로 인한 피부 상처, 발생 과정, 성숙 과정(예컨대 여드름), 유전자 비정상, 발생 비정상 및 환경적 손상을 포함한다.As used herein, the terms "skin damage" or "wound" can be used interchangeably and include, for example, scratches, cuts, torn wounds, pressed wounds, compression wounds, stretch damage, bite wounds, abrasions, Bullet wounds, explosion damage, body piercings, puncture wounds, burns, wind wounds, sun burns, chemical burns, surgical wounds, surgical interventions, medical interventions, host rejection after transplantation of cells, tissues or organs, drug effects, Pharmaceutical side effects, bedsores, radiation damage, skin wounds caused by cosmetics, developmental processes, maturation processes (such as acne), genetic abnormalities, developmental abnormalities and environmental damage.

본 발명에 의한 항염증용, 상처 치유용 또는 항노화용 조성물은 포공영, 승마, 산약 및 고본 추출물을 그 유효량으로 포함하는 약제학적 조성물 형태로 제조할 수 있으며, 당업계에서 통상적으로 사용하는 하나 또는 그 이상의 무독성, 약제학적으로 허용 가능한 담체, 보조제 또는 희석액 또는 다른 활성성분을 포함할 수 있다.The anti-inflammatory, wound healing or anti-aging composition according to the present invention may be prepared in the form of a pharmaceutical composition comprising an effective amount of pogongyoung, horse riding, powder and extract extracts, one or more commonly used in the art The above non-toxic, pharmaceutically acceptable carrier, adjuvant or diluent or other active ingredient may be included.

또한 본 발명에 의한 조성물은 약제학적으로 허용 가능한 담체와 부형제를 이용하여 공지의 방법으로 피부 외용제 형태로 제제화될 수 있다.The compositions according to the invention can also be formulated in the form of external preparations for the skin by known methods using pharmaceutically acceptable carriers and excipients.

또 본 발명에 의한 조성물은 오일 또는 수성매질에서 용액, 현탁액 또는 유화액의 형태가 되거나, 사용하기 전에 무균, 발열물질이 제거된 물로 녹여 사용하는 건조분말의 형태가 되어 피부 외용 제형으로 제형화될 수 있다. 유중수형 유화액은 올리브유 같은 식물성 기름 또는 액상 파라핀 같은 광물성 오일을 유상으로 하고, 대두레시틴(soy bean lecithin) 등의 자연산 인지질 및 소르비탄모노올레이트와 같은 무수헤시톨이나 지방산의 에스테르에서 유래된 것, 리옥시에틸렌소르비톨모노올레이트와 같이 무수헥시톨(hexitol anhydride)과 지방산에서 유래한 부분 에스테르를 에틸렌 옥사이드와 축합한 화합물들을 유화제로 하여 활성성분을 유화시킨 것이다.In addition, the composition according to the present invention may be in the form of a solution, a suspension or an emulsion in an oil or an aqueous medium, or in the form of a dry powder that is dissolved in sterile, pyrogen-free water before use, and may be formulated into an external skin formulation. have. Water-in-oil emulsions are derived from vegetable oils such as olive oil or mineral oils such as liquid paraffin, and are derived from natural phospholipids such as soy bean lecithin and esters of anhydrous hecitol or fatty acids such as sorbitan monooleate. The active ingredient is emulsified using compounds obtained by condensation of ethylene oxide with partial esters derived from anhydrous hexitol anhydride and fatty acids, such as lyoxyethylene sorbitol monooleate.

본 발명의 피부 외용제 조성물이 화장료로 제형화될 경우, 그 제형에 있어서 특별히 한정되는 바가 없으며 유연화장수, 수렴화장수, 영양화장수, 아이 크림, 영양 크림, 마사지 크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 파우더, 에센스 또는 팩 등의 제형을 가질 수 있다.When the external composition for skin of the present invention is formulated as a cosmetic, it is not particularly limited in the formulation, it is a softening longevity, astringent longevity, nourishing longevity, eye cream, nutrition cream, massage cream, cleansing cream, cleansing foam, cleansing water, It may have a formulation such as powder, essence or pack.

이하 본 발명을 하기 실시예 및 시험예에 의거하여 보다 구체적으로 설명한다. 그러나 이들 실시예 및 시험예는 본 발명에 대한 이해를 돕기 위한 것일 뿐, 본 발명의 범위가 이들 예로 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail based on the following Examples and Test Examples. However, these examples and test examples are only for helping the understanding of the present invention, the scope of the present invention is not limited to these examples.

[실시예 1] 한약재 추출물의 제조Example 1 Preparation of Herbal Medicine Extract

건조한 포공영, 승마, 산약 및 고본 1kg에 각각 80% 에탄올 수용액 5ℓ를 넣 고, 3회 환류 추출한 다음, 15℃에서 1일간 침적시켰다. 그 후, 여과포 여과와 원심분리를 통해 잔사와 여액을 분리하였고, 분리된 여액을 감압 농축하여 포공영, 승마, 산약 및 고본 추출물을 각각 얻었다.5 L of 80% ethanol aqueous solution was added to 1 kg of dry pogongyoung, horseback riding, powdered acid and high bone, and refluxed three times, followed by immersion at 15 ° C for 1 day. Thereafter, the residue and the filtrate were separated through filter cloth filtration and centrifugation. The separated filtrate was concentrated under reduced pressure to obtain pogongyoung, horse riding, powdered acid and kobon extract, respectively.

[시험예 1] 육안적 형태를 통한 상처 치유 활성Test Example 1 Wound Healing Activity through Visual Form

인간의 각질형성 세포인 HaCaT 세포는 한국 세포주은행(Korean Cell Line Bank;Seoul, Korea)에서 분양받아 사용하였다. HaCaT 세포를 10% (v/v) FBS, 페니실린 100U/ml 및 스트렙토마이신 100㎍/ml를 포함하는 DMEM 배지에 주입하고 37℃, 5% CO2 공급조건을 갖춘 동물세포배양기에서 배양하였다. 공(Well) 당 1.5×106 농도로 준비된 HaCaT 세포를 24 시간 배양하여 세포 단일층을 형성시킨 후, HaCaT 세포 단일층을 p200 피펫 팁으로 "긁힘-손상"을 유도하였다. "긁힘 손상"된 세포층을 실시예 1에서 제조한 포공영, 승마, 산약 및 고본 추출물을 각각 10ppm 농도로 처리한 배양 배지에서 24시간 배양한 후 긁힘 상처가 회복되는 정도를 확인하였으며, 그 결과를 도 1에 나타내었다. 음성 대조군으로는 상기 한약재 추출물들을 녹이는데 사용한 DMSO를 동량 처리하였다.HaCaT cells, which are human keratinocytes, were distributed and used by Korean Cell Line Bank (Seoul, Korea). HaCaT cells were injected into DMEM medium containing 10% (v / v) FBS, 100 U / ml penicillin and 100 μg / ml of streptomycin and cultured in an animal cell incubator with 37 ° C., 5% CO 2 feed conditions. HaCaT cells prepared at a concentration of 1.5 × 10 6 per well were incubated for 24 hours to form cell monolayers, and then HaCaT cell monolayers were “scratched-damaged” with a p200 pipette tip. In the culture medium in which the "scratch damaged" cell layer was treated at 10 ppm concentrations of pogongyoung, horse riding, powdered acid and medicated extract prepared in Example 1, respectively. After culturing for 24 hours, the degree of recovery of the scratches was confirmed, and the results are shown in FIG. 1. As a negative control, the same amount of DMSO used to dissolve the herbal extracts was treated.

또한 한약재 복합 처방에 의한 변화를 확인하기 위하여 상기 실시예 1에서 제조한 포공영, 승마, 산약 및 고본 추출물을 1:1:1:1의 중량비로 혼합한 복합 추출물을 준비하였다. 상기와 동일하게, "긁힘 손상"된 세포층을 복합 추출물이 10ppm 농도로 처리된 배양배지에서 24시간 배양한 후 긁힘 상처가 회복되는 정도를 확인하였으며, 그 결과를 도 1에 나타내었다. In addition, in order to confirm the change by the herbal medicine composite formulation, poongyoung, horseback riding, powdered powder and kobon extract prepared in Example 1 was prepared in a composite extract mixed in a weight ratio of 1: 1: 1: 1. In the same manner as above, after the incubation for 24 hours in a culture medium treated with a complex extract of the "scratch damaged" cell layer 10ppm concentration was confirmed the extent of the scratches recovered, the results are shown in FIG.

도 1의 결과에서, 음성 대조군이 처리된 세포의 "긁힘 손상"은 24 시간 후에 상대적으로 치유되지 않은 채로 남아 있었는데 반해, 실시예 1에서 제조한 한약재 추출물들이 처리된 세포에서는 상처 가장자리의 세포 증식과 이동으로 "긁힘-손상"이 치유되어 24시간 후 긁힌 면적이 감소되었다. 특히 복합 추출물을 처리한 세포에서의 치유 효과가 추출물을 단독으로 사용하였을 때보다 더 우수하였다.In the results of FIG. 1, the "scratch damage" of the cells treated with the negative control remained relatively untreated after 24 hours, whereas in the cells treated with the herbal extracts prepared in Example 1 The movement healed the “scratch-damage” and reduced the scratched area after 24 hours. In particular, the healing effect in the cells treated with the composite extract was better than when using the extract alone.

[시험예 2] 항염증 및 각질 성장인자 수용체와 해독작용 효소 유도 효과Test Example 2 Anti-inflammatory and Keratin Growth Factor Receptor and Detoxification Enzyme Induction Effect

인간의 각질형성 세포인 HaCaT 세포는 한국 세포주은행(Korean Cell Line Bank;Seoul, Korea)에서 분양받아 사용하였다. HaCaT 세포를 10% (v/v) FBS, 페니실린 100U/ml 및 스트렙토마이신 100㎍/ml를 포함하는 DMEM 배지에 주입하고 37℃, 5% CO2 공급조건을 갖춘 동물세포배양기에서 배양하였다. 공(Well) 당 1.5×106 농도로 준비된 HaCaT 세포에 FBS가 포함되지 않은 배지로 3시간 동안 적응시켰다. 이후 실시예 1에서 제조한 포공영, 승마, 산약 및 고본 추출물과 이들을 1:1:1:1의 중량비로 혼합한 복합 추출물을 각각 10 ppm 농도로 2시간 동안 전처리하고 1㎍/ml 농도로 LPS를 첨가하여 8시간 동안 추가 배양하였다. 총 RNA는 TRIzolTM(GIBCO BRL, MD, USA)을 사용하여 추출하였고 -80℃에서 보관하였다. HaCaT cells, which are human keratinocytes, were distributed and used by Korean Cell Line Bank (Seoul, Korea). HaCaT cells were injected into DMEM medium containing 10% (v / v) FBS, 100 U / ml penicillin and 100 μg / ml of streptomycin and cultured in an animal cell incubator with 37 ° C., 5% CO 2 feed conditions. HaCaT cells prepared at a concentration of 1.5 × 10 6 per well were adapted for 3 hours with medium without FBS. Thereafter, the pogongyoung, horse riding, powder and kobon extracts prepared in Example 1 and the complex extracts mixed at a weight ratio of 1: 1: 1: 1 were pretreated at 10 ppm for 2 hours and LPS at 1 μg / ml. Addition was further incubated for 8 hours. Total RNA was extracted using TRIzol (GIBCO BRL, MD, USA) and stored at −80 ° C.

총 RNA 1㎍을 50mM 트리스-HCl(Tris-HCl, pH 8.3), 75mM KCl, 3mM MgCl2, 0.1M DTT, 10mM dNTP 및 40 유닛/㎕ RNase 저해제가 함유된 역전사 반응 완충액 25㎕에 넣고, 0.5㎍/㎕ 올리고(dT)16의 프라이머와 200 유닛 수퍼스크립트 II[SuperScript II, 집코비알엘(GiboBRL)]의 역전사 중합효소를 첨가하여 42℃에서 1시간 반응시킨 다음 역전사 반응 용액 2.5㎕를 엠플리택(AmpliTaq) DNA 중합효소[0.04U, 퍼킨 엘멀, 쉘튼, 씨티(Perkin Elmer, Shelton, CT)], 50mM 트리스(pH 8.3), 0.25mg/ml 우혈청알부민, 3mM MgCl2, 0.25mM dNTPs, SYBR 그린 I의 1/50,000 희석액[몰레큘라 프로브, 유진, 오알(Molecular Probes, Eugene, OR)]이 함유된 PCR 반응 완충액 50ℓ에 섞고, 10μM의 프라이머를 첨가하여 94℃에서 30초간 변성, 53℃에서 30초간 어닐링 및 72℃에서 1분간 확장하는 사이클을 30회 수행하였다. 1 μg total RNA was placed in 25 μl of reverse transcription reaction buffer containing 50 mM Tris-HCl, pH 8.3, 75 mM KCl, 3 mM MgCl 2 , 0.1 M DTT, 10 mM dNTP and 40 units / μl RNase inhibitor, and 1 μg / μl oligo (dT) 16 primer and 200 units of SuperScript II (GiboBRL) reverse transcriptase were added and reacted at 42 ° C. for 1 hour, followed by 2.5 μl of reverse transcription reaction solution. (AmpliTaq) DNA polymerase [0.04U, Perkin Elmer, Shelton, CT], 50 mM Tris, pH 8.3, 0.25 mg / ml bovine serum albumin, 3 mM MgCl 2 , 0.25 mM dNTPs, SYBR Mix 50 L of PCR reaction buffer containing 1 / 50,000 dilution of Green I (Molecular Probes, Eugene, OR), add 10 μM primer, denature at 94 ° C for 30 seconds, at 53 ° C. Thirty cycles of annealing for 30 seconds and expansion for 1 minute at 72 ° C. were performed.

상대적인 mRNA 레벨은 아이사이클러(ICycler) 소프트웨어를 이용하여 SYBR 그린 I 형광 변화를 측정함으로써 분석하였다. 각각의 프라이머는 상처치료 효능 및 염증억제 기능, 해독작용을 가진 물질을 분석하여 발행된 SCI급 논문들을 토대로 제작하였으며 각각의 염기서열은 하기 표 1에 나타내었다. 내부 표준물질로 GAPDH(glyceraldehyde 3-phosphate dehydrogenase)를 사용하여 유전자의 정량적 발현 수준을 보정하였다.Relative mRNA levels were analyzed by measuring SYBR Green I fluorescence changes using ICycler software. Each primer was prepared on the basis of published SCI papers by analyzing materials having wound healing efficacy, inflammation inhibitory function, and detoxification activity, and each base sequence is shown in Table 1 below. GAPDH (glyceraldehyde 3-phosphate dehydrogenase) was used as an internal standard to correct quantitative expression levels of genes.

PCR에 사용된 프라이머 서열 Primer sequence used for PCR 유전자/NCBI Gene IDGene / NCBI Gene ID 프라이머 서열Primer sequence 서열 번호Sequence number 증폭 산물크기 (bp)Amplification Product Size (bp) PCR 반응온도(℃)PCR reaction temperature (℃) 변성 denaturalization 어닐링Annealing 확장expansion GAPDH/ 2597GAPDH / 2597 5'-ATC CCA TCA CCA TCT TCC AG-3'5'-ATC CCA TCA CCA TCT TCC AG-3 ' 1One 579579 9494 5858 7272 5'-CCT GCT TCA CCA CCT TCT TG -3'5'-CCT GCT TCA CCA CCT TCT TG -3 ' 22 iNOS/ 4843iNOS / 4843 5'-ATG TCC GAA GCA AAC ATC AC -3'5'-ATG TCC GAA GCA AAC ATC AC -3 ' 33 401401 9494 5858 7272 5'-TAA TGT CCA GGA AGT AGG TG -3'5'-TAA TGT CCA GGA AGT AGG TG -3 ' 44 IL-1β/ 3553IL-1β / 3553 5'-TGC AGA GTT CCC CAA CTG GTA CAT C -3'5'-TGC AGA GTT CCC CAA CTG GTA CAT C -3 ' 55 387387 9494 5858 7272 5'-GTG CTG CCT AAT GTC CCC TTG AAT C -3'5'-GTG CTG CCT AAT GTC CCC TTG AAT C -3 ' 66 TNF-α/ 7124TNF-α / 7124 5'-CCT GTA GCC CAC GTC GTA GC -3'5'-CCT GTA GCC CAC GTC GTA GC -3 ' 77 374374 9494 5858 7272 5'-TTG ACC TCA GCG CTG AGT TG -3'5'-TTG ACC TCA GCG CTG AGT TG -3 ' 88 FGFR2-Ⅲb/2263FGFR2-IIIb / 2263 5'-ACT CGG GGA TAA ATA GTT CCA A-3'5'-ACT CGG GGA TAA ATA GTT CCA A-3 ' 99 357357 9494 6060 7070 5'-CCT TAC ATA TAT ATT CCC CAG CAT-3'5'-CCT TAC ATA TAT ATT CCC CAG CAT-3 ' 1010 NQO1/ 1728NQO1 / 1728 5'-TGA AGG ACC CTG CGA ACT TTC-3'5'-TGA AGG ACC CTG CGA ACT TTC-3 ' 1111 185185 9595 6161 7070 5'-GAA CAC TCG CTC AAA CCA GC-3'5'-GAA CAC TCG CTC AAA CCA GC-3 ' 1212 GSTP1/ 2950GSTP1 / 2950 5'-AGG ACC TCC GCT GCA AAT AC-3'5'-AGG ACC TCC GCT GCA AAT AC-3 ' 1313 105105 9595 6060 7070 5'-GGG TCT CAA AAG GCT TCA GTT G-3'5'-GGG TCT CAA AAG GCT TCA GTT G-3 ' 1414 PRDX1/ 5052PRDX1 / 5052 5'-CGG AGA TCA TTG CTT TCA GTG A-3'5'-CGG AGA TCA TTG CTT TCA GTG A-3 ' 1515 113113 9595 6060 7070 5'-AGG TGT ATT GAC CCA TGC TAG AT-3'5'-AGG TGT ATT GAC CCA TGC TAG AT-3 ' 1616

본 발명에서는 염증 매개인자(proinflammatory mediator) NO와 관련된 인자인 iNOS와 또 다른 염증관련 인자인 IL-1β와 TNF-α 유전자의 발현에 미치는 한약재 추출물의 효과를 알아보기 위하여 RT-PCR 분석을 실시하였으며, 그 결과를 도 2a 내지 2c에 나타내었다. 각 PCR 산물은 GAPDH에 대하여 정량화되었다. 일원배치 분산분석(one-way ANOVA)에 이은 Tukey HSD 사후 검증(post hoc test)에 의한 유의수준은 **P<0.01, *P<0.05 대비 LPS+ 군으로 나타내었다. iNOS, IL-1β 및 TNF-α는 상처치료 과정 중 염증기에서 중요한 작용을 하는 염증관련 인자로서 많은 실험 논문들에서도 염증억제의 효능을 확인하는데 자주 사용되고 있다. iNOS, IL-1β와 TNF-α는 지질다당류(lipopolysaccharide, LPS)로 유도된 염증반응에서 다양하게 발현되는 유전자이다.In the present invention, RT-PCR analysis was performed to investigate the effects of herbal extracts on the expression of iNOS, a factor associated with proinflammatory mediator NO, and the expression of IL-1β and TNF-α, another inflammation-related factor. The results are shown in Figures 2a to 2c. Each PCR product was quantified for GAPDH. One-way ANOVA followed by Tukey HSD post hoc test showed significant levels of LPS + compared to ** P <0.01 and * P <0.05. iNOS, IL-1β and TNF-α are inflammation-related factors that play an important role in the inflammatory phase during wound healing and are frequently used to confirm the efficacy of inflammation in many experimental papers. iNOS, IL-1β and TNF-α are genes that are expressed in various ways in the inflammatory response induced by lipopolysaccharide (LPS).

도 2a 내지 2c의 결과를 살펴보면, 지질다당류(lipopolysaccharide, LPS)를 처리하지 않은 세포에 비해 LPS 처리 세포들은 각각의 유전자가 과다 발현되었고, 상기 한약재 추출물의 처리는 iNOS와 IL-1β, TNF-α 유전자 발현을 강하게 억제하였다. 또한 한약재 복합 처방 추출물은 각각을 단독으로 사용하였을 때 보다 더 뛰어난 효능을 나타내었다. Referring to the results of FIGS. 2A to 2C, LPS-treated cells were overexpressed in respective genes, compared to cells not treated with lipopolysaccharide (LPS), and the treatment of the herbal extracts was iNOS, IL-1β, and TNF-α. Gene expression was strongly inhibited. In addition, the herbal herbal extracts showed better efficacy than when used alone.

또한 각질형성세포 성장인자 수용체(FGFR2-Ⅲb) 유전자의 발현은 세포 증식 효과와 상관 관계를 가진다고 보고되었다(Nagy N, Bata-Cs

Figure 112008056412932-PAT00001
go Z, Kopasz N, Szeg C, Pivarcsi A, Koreck A, Dobozy A, Kem
Figure 112008056412932-PAT00002
y L, Sz
Figure 112008056412932-PAT00003
ll M. The expression of keratinocyte growth factor receptor (FGFR2-Ⅲb) correlates with the high proliferative rate of HaCaT keratinocytes. Exp Dermatol. 2006 Aug;15(8):596-605). 실시예 1에서 제조한 포공영, 승마, 산약 및 고본 단독 추출물과 이들을 1:1:1:1의 중량비로 혼합한 복합 추출물에 의한 각질형성세포 성장인자 수용체(FGFR2-Ⅲb) 유전자의 발현 유도 효과를 측정한 결과를 도 3에 나타내었다. 도 3의 결과에서, 실시예 1에서 제조한 포공영, 승마, 산약 및 고본 추출물 및 이들의 복합 추출물이 모두 각질형성세포 성장인자 수용체 유전자의 발현을 유도하였으며, 특히 단독 추출물보다는 이들의 혼합한 복합 추출물에 의한 각질형성세포 성장인자 수용체(FGFR2-Ⅲb) 유전자의 발현 유도 효과가 더 높았다.In addition, expression of keratinocyte growth factor receptor (FGFR2-IIIb) genes has been reported to correlate with cellular proliferative effects (Nagy N, Bata-Cs).
Figure 112008056412932-PAT00001
go Z, Kopasz N, Szeg C, Pivarcsi A, Koreck A, Dobozy A, Kem
Figure 112008056412932-PAT00002
y L, Sz
Figure 112008056412932-PAT00003
ll M. The expression of keratinocyte growth factor receptor (FGFR2-IIIb) correlates with the high proliferative rate of HaCaT keratinocytes. Exp Dermatol. 2006 Aug; 15 (8): 596-605) . Induction effect of the keratinocyte growth factor receptor (FGFR2-IIIb) gene by the extract of pogongyoung, horse riding, powder and kobon alone extract prepared in Example 1 and a complex extract mixed with a weight ratio of 1: 1: 1: 1 The measured result is shown in FIG. In the results of Figure 3, pogongyoung, horse riding, powder and extract extracts and their complex extracts prepared in Example 1 all induced the expression of keratinocyte growth factor receptor genes, in particular the complex extracts thereof mixed rather than the extract alone Expression of keratinocyte growth factor receptor (FGFR2-IIIb) gene was higher.

또한 GSTs, NQO1 및 PRDX1와 같은 해독 유전자의 발현은 산화적 손상으로부터의 세포 보호 작용을 유도한다고 보고되었다(Xie C, Lovell MA, Xiong S, Kindy MS, Guo J, Xie J, Amaranth V, Montine TJ, Markesbery WR. Expression of glutathione-S-transferase isozyme in the SY5Y neuroblastoma cell line increases resistance to oxidative stress. Free Radic Biol Med. 2001 Jul;31(1):73-81; Liu Y, Kern JT, Walker JR, Johnson JA, Schultz PG, Luesch H. A genomic screen for activators of the antioxidant response element. Proc Natl Acad Sci U S A. 2007 Mar; 104(12):5205-10; Carcinogenesis. 2000 May;21(5):1013-6. Induction of murine intestinal and hepatic peroxiredoxin MSP23 by dietary butylated hydroxyanisole. Ishii T, Itoh K, Akasaka J, Yanagawa T, Takahashi S, Yoshida H, Bannai S, Yamamoto M). 도 4a 내지 4c는 실시예 1에서 제조한 포공영, 승마, 산약 및 고본 단독 추출물과 이들을 1:1:1:1의 중량비로 혼합한 복합 추출물에 의한 해독 유전자인 GSTs, NQO1 및 PRDX1의 발현 유도 효과를 측정한 결과이다. 실시예 1에서 제조한 포공영, 승마, 산약 및 고본 추출물 및 이들의 복합 추출물이 모두 해독 유전자인 GSTs, NQO1 및 PRDX1의 발현을 유도하였으며, 특히 단독 추출물보다는 이들을 혼합한 복합 추출물에 의한 GSTs, NQO1 및 PRDX1의 발현 유도 효과가 더 높았다.It has also been reported that expression of detoxification genes such as GSTs, NQO1 and PRDX1 induces cellular protective action from oxidative damage (Xie C, Lovell MA, Xiong S, Kindy MS, Guo J, Xie J, Amaranth V, Montine TJ , Markesbery WR.Expression of glutathione-S-transferase isozyme in the SY5Y neuroblastoma cell line increases resistance to oxidative stress.Free Radic Biol Med. 2001 Jul; 31 (1): 73-81; Liu Y, Kern JT, Walker JR, Johnson JA, Schultz PG, Luesch H. A genomic screen for activators of the antioxidant response element.Proc Natl Acad Sci US A. 2007 Mar; 104 (12): 5205-10; Carcinogenesis. 2000 May; 21 (5): 1013 -6.Induction of murine intestinal and hepatic peroxiredoxin MSP23 by dietary butylated hydroxyanisole.Ishii T, Itoh K, Akasaka J, Yanagawa T, Takahashi S, Yoshida H, Bannai S, Yamamoto M). 4a to 4c show the effect of inducing the expression of GSTs, NQO1 and PRDX1, which are the detoxification genes of the pogongyoung, horse riding, powder and kobon extracts prepared in Example 1 and the complex extracts mixed at a weight ratio of 1: 1: 1: 1 Is the result of measurement. The pogongyoung, horse riding, powder and extract extract and the combination extract thereof prepared in Example 1 all induced the expression of the detoxification genes GSTs, NQO1 and PRDX1, in particular GSTs, NQO1 and The expression inducing effect of PRDX1 was higher.

[시험예 3] UV에 의한 NF-κB 활성 증가 억제 효과Test Example 3 Inhibitory Effect of UV on NF-κB Activity Increase

인체 각질형성세포주인 HaCaT세포를 106개의 밀도로 100mm 세포 배양 접시에서 배양하였고, FS40 램프[웨스팅하우스, 피츠버그, 피에이., 미국(Westinghouse, Pittsburgh, PA, USA)]를 이용하여 자외선 B를 10mJ/㎠로 조사한 후, 실시예 1에서 제조한 포공영, 승마, 산약 및 고본 추출물을 각각 10ppm 씩 포함한 배지로 교체하였다. HaCaT cells, a human keratinocyte cell line, were cultured in 100 mm cell culture dishes at 10 6 densities, and UVB was irradiated using FS40 lamps (Westinghouse, Pittsburgh, P., USA). After irradiating at 10mJ / cm 2, pogongyoung, horseback riding, powdering and gobon extract prepared in Example 1 was replaced with a medium containing 10ppm each.

배양 6-24시간 후 트랜스팩터 추출 키트(TransFactor extraction kit)[비디 바이오사이언스 클론테크, 산 호세, 씨에이, 미국(비디 바이오사이언스 클론테크, 산 호세, 캘리포니아주, 미국)]를 이용하여 핵 추출물을 얻고 그 후 트랜스팩터 키트(비디 바이오사이언스 클론테크, 산 호세, 캘리포니아주, 미국)를 이용하여 NF-κB 활성을 측정하였으며, 그 결과를 도 5에 나타내었다.After 6-24 hours of culture, the nuclear extract was extracted using a TransFactor extraction kit (BD Bioscience Clontech, San Jose, C.A., USA (BD Bioscience Clontech, San Jose, CA, USA)). NF-κB activity was measured using a transfactor kit (BD Bioscience Clontech, San Jose, CA, USA), and the results are shown in FIG. 5.

도 5의 결과에서, 처음에는 자외선 조사에 의해 NF-κB 활성이 크게 증가하였으나, 실시예 1의 한약재 추출물을 처리한 이후에 자외선에 의한 NF-κB 활성 증가가 억제되었다.In the results of FIG. 5, the NF-κB activity was greatly increased by ultraviolet irradiation at first, but the increase of NF-κB activity by ultraviolet rays was suppressed after the herbal extract of Example 1 was treated.

[시험예 4] UV에 의한 MMP-1 생성 증가 억제 효과Test Example 4 Effect of Inhibiting the Increase of MMP-1 Production by UV

인체 각질형성세포주인 HaCaT세포를 106개의 밀도로 100mm 세포 배양 접시에서 배양하였고, 실시예 1에서 제조한 포공영, 승마, 산약 및 고본 추출물을 각각 10ppm씩 전처리한 후 FS40 램프(웨스팅하우스, 피츠버그, 펜실베니아주, 미국)를 이용하여 자외선 B를 10mJ/㎠로 조사하였다. 상기 포공영, 승마, 산약 및 고본 추출물을 10ppm씩 포함한 배지로 교체한 후 48시간 동안 배양한 후 생성된 MMP-1의 양을 ELISA 키트[아메르샴 파마시아(amersharm pharmacia), cat.#; RPN2610]를 이용하여 측정하였다. 각각 측정된 MMP-1의 양은 전체 단백질 대비 상대적 양으로 보정하였으며, 그 결과를 도 6에 나타내었다.HaCaT cells, a human keratinocyte cell line, were cultured in a 100 mm cell culture dish at a density of 10 6 , and pretreated with poppongyoung, horseback riding, powder and gobon extracts prepared in Example 1 by 10 ppm, respectively, and then FS40 lamps (Westinghouse, Pittsburgh, Ultraviolet B was irradiated at 10 mJ / cm 2 using Pennsylvania, USA. After replacing the pogongyoung, horse riding, powdered acid and kobon extract with a medium containing 10ppm each incubation for 48 hours, the amount of MMP-1 produced was measured by ELISA kit [amersharm pharmacia, cat. #; RPN2610]. Each measured amount of MMP-1 was corrected relative to the total protein, and the results are shown in FIG. 6.

도 6의 결과에서, 처음에는 자외선 조사에 의해 MMP-1 생성이 증가하였으나 실시예 1에서 제조한 포공영, 승마, 산약 및 고본 추출물을 처리함으로써 자외선에 의한 MMP-1 생성 증가가 유의적으로 억제되었다.In the results of FIG. 6, MMP-1 production was initially increased by UV irradiation, but the increase in MMP-1 production by UV treatment was significantly suppressed by treating pogongyoung, horse riding, powdered powder and kobon extract prepared in Example 1. .

[시험예 5] 노화에 따른 MMP-1 생성 증가 억제 효과Test Example 5 Inhibition Effect of MMP-1 Production by Aging

인간 진피 섬유아세포를 10% 우태아혈청을 포함한 DMEM 배지에서 실시예 1에서 제조한 포공영, 승마, 산약 및 고본 추출물을 10ppm씩 첨가하거나 또는 첨가하지 않은 상태(무처리군)로 배양하였다. 80∼90%의 밀도에 도달했을 때 1/2로 계대 배양하여 패시지5, 패시지10, 패시지20 및 패시지30일 때 세포를 얻어 생성된 MMP-1의 양을 측정하였고, 그 결과를 도 7에 나타내었다. Human dermal fibroblasts were cultured in DMEM medium containing 10% fetal calf serum with or without 10 ppm of pogongyoung, horse riding, powder and kobon extracts prepared in Example 1 (untreated group). When reaching a density of 80 to 90%, the cells were passaged at 1/2 to obtain cells at Passage 5, Passage 10, Passage 20 and Passage 30, and the amount of MMP-1 produced was measured. Indicated.

도 7의 결과에서, 본 발명에 의한 포공영, 승마, 산약 및 고본 추출물은 증식하는 노화 세포 모델에서 노화에 따른 MMP-1 생성 증가를 억제하였다. In the results of Figure 7, pogongyoung, horse riding, powder and extract extract according to the present invention inhibited the increase of MMP-1 production with aging in the proliferating aging cell model.

상기에서 살펴본 바와 같이, 본 발명에서 유효성분으로 사용하는 포공영, 승마, 산약 및 고본 추출물은 염증관련 인자들을 억제하고 재상피화를 촉진시킴으로써 상처치유 과정 중 염증기에서 증식기로의 진행을 빠르게 도와주고 증식기 동안에는 세포 증식을 자극하고 상처치료에 도움을 주는 인자들을 분비하는데 도움을 주어 결합조직 세포들의 성숙을 도와주었다. 또한 항염증 효과와 함께 해독 작용에 관여하는 효소들의 유전자 발현을 증가시킴으로써, UV 등 외부 자극에 의한 피부 손상을 억제하여 피부 노화를 억제하는 효능을 가졌다. 이들 성분을 단독으로 사용한 것보다 복합 처방한 것이 더 우수한 효과를 가졌다. As described above, pogongyoung, horse riding, powder and herbal extracts used as an active ingredient in the present invention to suppress the inflammation-related factors and promote re-epithelialization to help the progression from the inflammatory phase to the proliferative phase during wound healing and during the growth phase It helped the maturation of connective tissue cells by helping to secrete factors that stimulate cell proliferation and help in wound healing. In addition, by increasing the gene expression of enzymes involved in the detoxification action with an anti-inflammatory effect, it has the effect of inhibiting skin aging by inhibiting skin damage caused by external stimuli such as UV. The combined regimen had a better effect than using these components alone.

따라서, 본 발명에 의한 포공영, 승마, 산약 및 고본 추출물은 전반적인 상처치료 과정 중에 초기 과정인 염증기와 성숙기에 전체적으로 조금씩 도움을 주어 치료시간을 단축시키는 효능을 보이는 바, 본 발명에서는 상기 포공영, 승마, 산약 및 고본 추출물을 유효성분으로 함유하는 항염증제 또는 상처치유제를 제공할 수 있었다. 또한 본 발명에서는 상기 포공영, 승마, 산약 및 고본 추출물을 유효성분으로 함유하고, 항염증 또는 해독 작용을 통해 UV 등 외부 자극에 의한 피부 손상을 억제하여 피부 노화를 억제하는 항노화제를 제공할 수 있다.Therefore, pogongyoung, horse riding, powder and extract extract according to the present invention shows an effect of shortening the treatment time by little by little as a whole help to the inflammatory and mature phase of the initial process during the overall wound treatment process, the pogongyoung, horse riding, It was possible to provide an anti-inflammatory or wound healing agent containing a powder and an extract as an active ingredient. In addition, the present invention may provide an anti-aging agent containing the pogongyoung, horse riding, powder and extract extract as an active ingredient, and inhibits skin aging by external stimulation such as UV through anti-inflammatory or detoxification action have.

[제형예 1] 영양화장수Formulation Example 1 Nutritional Cosmetics

하기 표 2에 기재된 조성에 따라 통상적인 방법으로 영양화장수를 제조하였다.Nutritional longevity was prepared according to the composition described in Table 2 below in a conventional manner.

성분ingredient 함량(중량 %)Content (% by weight) 정제수Purified water 잔량Remaining amount 글리세린glycerin 8.08.0 부틸렌글리콜Butylene glycol 4.04.0 히알루론산 추출물Hyaluronic acid extract 5.05.0 베타글루칸Beta Glucan 7.07.0 카보머Carbomer 0.10.1 포공영, 승마, 산약 또는 고본 추출물Pogongyoung, horse riding, pesticide or herbal extract 0.050.05 카프릴릭/카프릭 트리글리세라이드Caprylic / Capric Triglycerides 8.08.0 스쿠알란Squalane 5.05.0 세테아릴 글루코사이드Cetearyl Glucoside 1.51.5 소르비탄 스테아레이트Sorbitan stearate 0.40.4 세테아릴 알코올Cetearyl Alcohol 1.01.0 방부제antiseptic 적량Quantity incense 적량Quantity 색소Pigment 적량Quantity 트리에탄올아민Triethanolamine 0.10.1

[제형예 2] 영양크림Formulation Example 2 Nutrition Cream

하기 표 3에 기재된 조성에 따라 통상적인 방법으로 영양크림을 제조하였다.Nutritional cream was prepared in a conventional manner according to the composition shown in Table 3.

성분ingredient 함량(중량%)Content (% by weight) 정제수Purified water 잔량Remaining amount 글리세린glycerin 3.03.0 부틸렌글리콜Butylene glycol 3.03.0 유동파라핀Liquid paraffin 7.07.0 베타글루칸Beta Glucan 7.07.0 카보머Carbomer 0.10.1 포공영, 승마, 산약 또는 고본 추출물Pogongyoung, horse riding, pesticide or herbal extract 3.03.0 카프릴릭/카프릭 트리글리세라이드Caprylic / Capric Triglycerides 3.03.0 스쿠알란Squalane 5.05.0 세테아릴 글루코사이드Cetearyl Glucoside 1.51.5 소르비탄 스테아레이트Sorbitan stearate 0.40.4 폴리솔베이트 60Polysorbate 60 1.21.2 방부제antiseptic 적량Quantity incense 적량Quantity 색소Pigment 적량Quantity 트리에탄올아민Triethanolamine 0.10.1

[제형예 3] 마사지 크림Formulation Example 3 Massage Cream

하기 표 4에 기재된 조성에 따라 통상적인 방법으로 마사지 크림을 제조하였다.To prepare a massage cream in a conventional manner according to the composition described in Table 4.

성분ingredient 함량(중량%)Content (% by weight) 정제수Purified water 잔량Remaining amount 글리세린glycerin 8.08.0 부틸렌글리콜Butylene glycol 4.04.0 유동파라핀Liquid paraffin 45.045.0 베타글루칸Beta Glucan 7.07.0 카보머Carbomer 0.10.1 포공영, 승마, 산약 또는 고본 추출물Pogongyoung, horse riding, pesticide or herbal extract 1.01.0 카프릴릭/카프릭 트리글리세라이드Caprylic / Capric Triglycerides 3.03.0 밀납Beeswax 4.04.0 세테아릴 글루코사이드Cetearyl Glucoside 1.51.5 세스퀴 올레인산 소르비탄Sesqui oleic acid sorbitan 0.90.9 바세린Vaseline 3.03.0 방부제antiseptic 적량Quantity incense 적량Quantity 색소Pigment 적량Quantity 파라핀paraffin 1.51.5

[제형예 4] 팩[Formulation Example 4] Pack

하기 표 5에 기재된 조성에 따라 통상적인 방법으로 팩을 제조하였다.To prepare a pack in a conventional manner according to the composition described in Table 5.

성분ingredient 함량(중량%)Content (% by weight) 정제수Purified water 잔량Remaining amount 글리세린glycerin 4.04.0 폴리비닐알콜Polyvinyl alcohol 15.015.0 히알루론산 추출물Hyaluronic acid extract 5.05.0 베타글루칸Beta Glucan 7.07.0 알란토인Allantoin 0.10.1 포공영, 승마, 산약 또는 고본 추출물Pogongyoung, horse riding, pesticide or herbal extract 0.50.5 노닐 페닐에테르Nonyl Phenyl Ether 0.40.4 폴리솔베이트 60Polysorbate 60 1.21.2 방부제antiseptic 적량Quantity incense 적량Quantity 색소Pigment 적량Quantity 에탄올ethanol 6.06.0

[제형예 5] 피부외용제 중 연고Formulation Example 5 Ointment in External Skin Preparation

하기 표 6에 기재된 조성에 따라 통상적인 방법으로 연고를 제조하였다.The ointment was prepared in a conventional manner according to the composition described in Table 6.

성분ingredient 함량(중량%)Content (% by weight) 정제수Purified water 잔량Remaining amount 글리세린glycerin 8.08.0 부틸렌글리콜Butylene glycol 4.04.0 유동파라핀Liquid paraffin 15.015.0 베타글루칸Beta Glucan 7.07.0 카보머Carbomer 0.10.1 포공영, 승마, 산약 또는 고본 추출물Pogongyoung, horse riding, pesticide or herbal extract 1.01.0 카프릴릭/카프릭 트리글리세라이드Caprylic / Capric Triglycerides 3.03.0 스쿠알란Squalane 1.01.0 세테아릴 글루코사이드Cetearyl Glucoside 1.51.5 소르비탄 스테아레이트Sorbitan stearate 0.40.4 세테아릴 알코올Cetearyl Alcohol 1.01.0 방부제antiseptic 적량Quantity incense 적량Quantity 색소Pigment 적량Quantity 밀납Beeswax 4.04.0

도 1은 시험관 내 상처 치유 측정법(in vitro wound healing assay)을 이용하여 포공영, 승마, 산약 및 고본 추출물의 상처 치유 효과 및 복합처방에 따른 상처치유 효능의 상승을 확인한 결과이다.1 is a result of confirming the wound healing effect of the pogongyoung, horse riding, powder and herbal extracts in accordance with the in vitro wound healing assay (in vitro wound healing assay) and the wound healing effect according to the complex prescription.

도 2a 내지 2c는 LPS로 염증을 유발한 HaCaT 세포에서 iNOS, IL-1β 및 TNF-α mRNAs의 발현량을 측정한 결과를 보여주는 그래프이다. Figure 2a to 2c is a graph showing the results of measuring the expression level of iNOS, IL-1β and TNF-α mRNAs in HaCaT cells induced inflammation with LPS.

도 3은 포공영, 승마, 산약 및 고본 추출물에 의한 각질형성세포 성장인자 수용체 (FGFR2-Ⅲb) 유전자의 발현 유도 효과를 보여주는 그래프이다. Figure 3 is a graph showing the expression inducing effect of the keratinocyte growth factor receptor (FGFR2-IIIb) gene by pogongyoung, horse riding, powder and extract extract.

도 4a 내지 4c는 포공영, 승마, 산약 및 고본 추출물에 의한 GSTP1, NQO1 및 PRDX1 유전자의 발현 변화를 측정한 결과이다Figures 4a to 4c is a result of measuring the change in the expression of GSTP1, NQO1 and PRDX1 gene by pogongyoung, horse riding, powder and kobon extract

도 5는 포공영, 승마, 산약 및 고본 추출물에 의한 NF-κB 활성 변화를 측정한 결과이다.Figure 5 is the result of measuring the change in NF-κB activity by pogongyoung, horse riding, powder and gobon extract.

도 6은 포공영, 승마, 산약 및 고본 추출물의 자외선 조사에 의한 MMP-1 발현 증가 억제 효과를 확인한 결과이다. 6 is a result confirming the inhibitory effect of the increase in MMP-1 expression by irradiation of pogongyoung, horse riding, powder and gobon extract.

도 7은 포공영, 승마, 산약 및 고본 추출물의 반복 계대 배양에 따른 세포 노화 시 증가하는 MMP-1 발현 억제 효과를 확인한 결과이다.7 is a result confirming the inhibitory effect of increased MMP-1 expression during cell aging according to repeated passage cultures of pogongyoung, horse riding, powder and gobon extract.

<110> AMOREPACIFIC CORPORATION <120> Skin external composition containing Taraxacum platycarpum H. Dahlsi, Cimicifuga heracleifolia, Dioscorea opposita or Angelica tenuissima Nakai <160> 16 <170> KopatentIn 1.71 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer for GAPDH <400> 1 atcccatcac catcttccag 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer for GAPDH <400> 2 cctgcttcac caccttcttg 20 <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer for iNOS <400> 3 atgtccgaag caaacatcac 20 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer for iNOS <400> 4 taatgtccag gaagtaggtg 20 <210> 5 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> IL-1 beta <400> 5 tgcagagttc cccaactggt acatc 25 <210> 6 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> primer for IL-1 beta <400> 6 gtgctgccta atgtcccctt gaatc 25 <210> 7 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer for TNF-alpha <400> 7 cctgtagccc acgtcgtagc 20 <210> 8 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer for TNF-alpha <400> 8 ttgacctcag cgctgagttg 20 <210> 9 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> primer for FGFR2-IIIb <400> 9 actcggggat aaatagttcc aa 22 <210> 10 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> primer for FGFR2-IIIb <400> 10 ccttacatat atattcccca gcat 24 <210> 11 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> primer for NQO1 <400> 11 tgaaggaccc tgcgaacttt c 21 <210> 12 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer for NQO1 <400> 12 gaacactcgc tcaaaccagc 20 <210> 13 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer for GSTP1 <400> 13 aggacctccg ctgcaaatac 20 <210> 14 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> primer for GSTP1 <400> 14 gggtctcaaa aggcttcagt tg 22 <210> 15 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> primer for PRDX1 <400> 15 cggagatcat tgctttcagt ga 22 <210> 16 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> primer for PRDX1 <400> 16 aggtgtattg acccatgcta gat 23 <110> AMOREPACIFIC CORPORATION <120> Skin external composition containing Taraxacum platycarpum H.          Dahlsi, Cimicifuga heracleifolia, Dioscorea opposita or Angelica          tenuissima Nakai <160> 16 <170> KopatentIn 1.71 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer for GAPDH <400> 1 atcccatcac catcttccag 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer for GAPDH <400> 2 cctgcttcac caccttcttg 20 <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer for iNOS <400> 3 atgtccgaag caaacatcac 20 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer for iNOS <400> 4 taatgtccag gaagtaggtg 20 <210> 5 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> IL-1 beta <400> 5 tgcagagttc cccaactggt acatc 25 <210> 6 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> primer for IL-1 beta <400> 6 gtgctgccta atgtcccctt gaatc 25 <210> 7 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer for TNF-alpha <400> 7 cctgtagccc acgtcgtagc 20 <210> 8 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer for TNF-alpha <400> 8 ttgacctcag cgctgagttg 20 <210> 9 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> primer for FGFR2-IIIb <400> 9 actcggggat aaatagttcc aa 22 <210> 10 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> primer for FGFR2-IIIb <400> 10 ccttacatat atattcccca gcat 24 <210> 11 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> primer for NQO1 <400> 11 tgaaggaccc tgcgaacttt c 21 <210> 12 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer for NQO1 <400> 12 gaacactcgc tcaaaccagc 20 <210> 13 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer for GSTP1 <400> 13 aggacctccg ctgcaaatac 20 <210> 14 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> primer for GSTP1 <400> 14 gggtctcaaa aggcttcagt tg 22 <210> 15 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> primer for PRDX1 <400> 15 cggagatcat tgctttcagt ga 22 <210> 16 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> primer for PRDX1 <400> 16 aggtgtattg acccatgcta gat 23  

Claims (4)

포공영, 승마, 산약 및 고본 추출물로 이루어진 군에서 선택된 1종 이상의 한약재 추출물을 유효성분으로 함유하는 항염증용 피부 외용제 조성물.Pogongyoung, horse riding, powdered herbal and anti-inflammatory skin external composition comprising as an active ingredient one or more herbal extracts selected from the group consisting of extracts. 포공영, 승마, 산약 및 고본 추출물로 이루어진 군에서 선택된 1종 이상의 한약재 추출물을 유효성분으로 함유하는 상처 치유용 피부 외용제 조성물.Pogongyoung, horse riding, powdered medicine and herbal extracts for wound healing skin composition containing as an active ingredient at least one herbal extract selected from the group consisting of extract. 포공영, 승마, 산약 및 고본 추출물로 이루어진 군에서 선택된 1종 이상의한약재 추출물을 유효성분으로 함유하는 항노화용 피부 외용제 조성물.Anti-aging skin composition for external aging containing at least one herbal extract selected from the group consisting of pogongyoung, horse riding, powdered acid and kobon extract as an active ingredient. 제 1항 내지 제 3항 중 어느 한 항에 있어서, 상기 한약재 추출물은 조성물 총 중량에 대하여 0.0001∼15 중량%로 함유되는 것임을 특징으로 하는 피부 외용제 조성물.The composition for external application for skin according to any one of claims 1 to 3, wherein the herbal extract is contained in an amount of 0.0001 to 15% by weight based on the total weight of the composition.
KR1020080076826A 2008-08-06 2008-08-06 External skin composition containing pogongyoung, horse riding, powder or extract extract KR101047644B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020080076826A KR101047644B1 (en) 2008-08-06 2008-08-06 External skin composition containing pogongyoung, horse riding, powder or extract extract

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020080076826A KR101047644B1 (en) 2008-08-06 2008-08-06 External skin composition containing pogongyoung, horse riding, powder or extract extract

Publications (2)

Publication Number Publication Date
KR20100018174A true KR20100018174A (en) 2010-02-17
KR101047644B1 KR101047644B1 (en) 2011-07-07

Family

ID=42088959

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020080076826A KR101047644B1 (en) 2008-08-06 2008-08-06 External skin composition containing pogongyoung, horse riding, powder or extract extract

Country Status (1)

Country Link
KR (1) KR101047644B1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021182873A1 (en) * 2020-03-13 2021-09-16 Medihelpline Co., Ltd. A topical composition comprising an extract of combined herbs comprising longanae arillus for the skin regeneration and the treatment or alleviation of skin wound and the use thereof.
WO2021182864A1 (en) * 2020-03-13 2021-09-16 Medihelpline Co., Ltd A topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof.
WO2021182865A1 (en) * 2020-03-13 2021-09-16 Medihelpline Co., Ltd. A topical composition comprising an extract of combined herbs comprising longanae arillus for tlsp inhibition and the treatment or alleviation of skin inflammatory disease and the use thereof.
KR102303936B1 (en) * 2020-03-13 2021-09-24 박옥남 topical composition comprising the extract of combined herbs comprising Longanae Arillus for the treatment or alleviation of skin ulcer
KR20210116235A (en) * 2020-03-13 2021-09-27 박옥남 topical composition comprising the extract of combined herbs comprising Longanae Arillus for the treatment or alleviation of skin scar
KR20210116234A (en) * 2020-03-13 2021-09-27 박옥남 topical composition comprising the extract of combined herbs comprising Longanae Arillus for TSLP inhibition and for the treatment or alleviation of skin inflammatory disease
WO2021201502A1 (en) * 2020-04-03 2021-10-07 Medihelpline Co., Ltd. An oral pharmaceutical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of inflammatory disease and the use thereof.
WO2023003292A1 (en) * 2021-07-19 2023-01-26 주식회사 메디헬프라인 Composition for preventing, ameliorating or treating skin wounds or inflammation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101891868B1 (en) 2015-12-31 2018-08-28 건국대학교 글로컬산학협력단 Natural complex extract composition for preventing skin aging and anti-inflammatory, natural cosmetic composition comprising that

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970005271A (en) * 1995-07-25 1997-02-19 신태율 Cosmetic composition containing extract of an asteraceae
KR20040092496A (en) * 2003-04-24 2004-11-04 김정태 Dried laver food added chiness medicinal herbs and the processing method thereof
KR100742378B1 (en) * 2005-05-17 2007-07-24 김정진 Composition containing herb medicine for treating atopic dermatitis
KR100771397B1 (en) * 2006-06-08 2007-10-30 인제대학교 산학협력단 Cosmetic composition comprising an extract of dandelion or luteolin isolated therefrom having anti-oxidant activity and anti-inflammatory activity

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021182873A1 (en) * 2020-03-13 2021-09-16 Medihelpline Co., Ltd. A topical composition comprising an extract of combined herbs comprising longanae arillus for the skin regeneration and the treatment or alleviation of skin wound and the use thereof.
WO2021182864A1 (en) * 2020-03-13 2021-09-16 Medihelpline Co., Ltd A topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof.
WO2021182865A1 (en) * 2020-03-13 2021-09-16 Medihelpline Co., Ltd. A topical composition comprising an extract of combined herbs comprising longanae arillus for tlsp inhibition and the treatment or alleviation of skin inflammatory disease and the use thereof.
KR102303936B1 (en) * 2020-03-13 2021-09-24 박옥남 topical composition comprising the extract of combined herbs comprising Longanae Arillus for the treatment or alleviation of skin ulcer
KR20210116235A (en) * 2020-03-13 2021-09-27 박옥남 topical composition comprising the extract of combined herbs comprising Longanae Arillus for the treatment or alleviation of skin scar
KR20210116234A (en) * 2020-03-13 2021-09-27 박옥남 topical composition comprising the extract of combined herbs comprising Longanae Arillus for TSLP inhibition and for the treatment or alleviation of skin inflammatory disease
CN115297879A (en) * 2020-03-13 2022-11-04 (株)美迪合伙来音 Topical composition comprising arillus longan combined crude drug extract for regenerating skin and treating or improving skin wound, and its application
CN115297880A (en) * 2020-03-13 2022-11-04 (株)美迪合伙来音 Topical composition comprising extract of crude drug comprising arillus longan for treating or improving skin ulcer, and its application
WO2021201502A1 (en) * 2020-04-03 2021-10-07 Medihelpline Co., Ltd. An oral pharmaceutical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of inflammatory disease and the use thereof.
WO2023003292A1 (en) * 2021-07-19 2023-01-26 주식회사 메디헬프라인 Composition for preventing, ameliorating or treating skin wounds or inflammation

Also Published As

Publication number Publication date
KR101047644B1 (en) 2011-07-07

Similar Documents

Publication Publication Date Title
KR101047644B1 (en) External skin composition containing pogongyoung, horse riding, powder or extract extract
JP6411580B2 (en) Composition for suppressing sebum production, containing three white grass extracts
Mingyu et al. The medicinal research and development of seabuckthorn
CN108685808B (en) Use of orchid callus extract for preparing skin care composition
KR101151093B1 (en) Cosmetic composition having anti-inflammation and skin regeneration effect
CN113679765A (en) Cortex dictamni extract and application thereof
CN111356468A (en) Composition for preventing or treating fibrotic disease comprising extract of Rhus toxicodendron
KR101499442B1 (en) Skin external composition containing Tussilago Farfara and Hibiscus Mutabilis flower extract
KR102526210B1 (en) Composition for improving skin regeneration and wound-healing comprising fermented Mastic Gum extract and method for manufacturing the same
CN111135124A (en) Skin external composition containing mixture of sucrose, indole-3-acetic acid and rose hip extract
KR101679391B1 (en) Composition for treating wound containing stellera chamaejasme extract or fraction thereof and method for treating wound in a subject
KR101722615B1 (en) Skin external composition containing Morus Bombycis Extract, Eclipta Prostrata Extract or Hovenia Dulcis Fruit Extract
KR101597762B1 (en) Composition for treating wound containing stellera chamaejasme extract or fraction thereof and method for treating wound in a subject
CN112972524A (en) Application of schisandra chinensis oil in inhibition of sebaceous gland activity
JP2012025777A (en) Vascularization inhibitor and external preparation
JP2022517983A (en) A pharmaceutical composition for the prevention or treatment of atopic dermatitis containing clonal stem cells.
KR20100059305A (en) Compositions for skin external application containing extracts of broussonetiae fructus
KR101574964B1 (en) - Skin external composition for anti-inflammation treating a wound or anti-aging containing ortho-dihydroxyisoflavones
EP3400937B1 (en) Use of butylidenephthalide
KR101463842B1 (en) Skin external composition for recovering inflammation or hurt containing extracts of herbal medicine
JPWO2019107440A1 (en) Cholesterol synthesis promoter
KR102257532B1 (en) Composition for skin regeneration after laser treatment comprising growth factor complex
KR20100054026A (en) Composition for skin external application comprising machilus thunbergii
KR20120058830A (en) Cosmetic composition for promoting the stemness of adipose-derived stem cell and proliferating skin cell containing hypericum extracts
KR20120058829A (en) Cosmetic composition for promoting the stemness of adipose-derived stem cell and proliferating skin cell containing sequoia callus cell extracts

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20140619

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20150617

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20160624

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20180702

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20190701

Year of fee payment: 9